tetano
Editor, Senior Moderator
Tomography
. 2022 Jul 30;8(4):1959-1973.
doi: 10.3390/tomography8040164.
Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies
Pedram Keshavarz[SUP] 1 2 [/SUP], Fereshteh Yazdanpanah[SUP] 3 [/SUP], Maryam Emad[SUP] 4 [/SUP], Azadeh Hajati[SUP] 4 [/SUP], Seyed Faraz Nejati[SUP] 4 [/SUP], Faranak Ebrahimian Sadabad[SUP] 4 [/SUP], Tamta Azrumelashvili[SUP] 5 [/SUP], Malkhaz Mizandari[SUP] 5 [/SUP], Steven S Raman[SUP] 1 [/SUP]
Affiliations
Abstract
We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.
Keywords: Janssen/Johnson & Johnson; Moderna; Pfizer-BioNTech; coronavirus; myocarditis.
. 2022 Jul 30;8(4):1959-1973.
doi: 10.3390/tomography8040164.
Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies
Pedram Keshavarz[SUP] 1 2 [/SUP], Fereshteh Yazdanpanah[SUP] 3 [/SUP], Maryam Emad[SUP] 4 [/SUP], Azadeh Hajati[SUP] 4 [/SUP], Seyed Faraz Nejati[SUP] 4 [/SUP], Faranak Ebrahimian Sadabad[SUP] 4 [/SUP], Tamta Azrumelashvili[SUP] 5 [/SUP], Malkhaz Mizandari[SUP] 5 [/SUP], Steven S Raman[SUP] 1 [/SUP]
Affiliations
- PMID: 36006062
- DOI: 10.3390/tomography8040164
Abstract
We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.
Keywords: Janssen/Johnson & Johnson; Moderna; Pfizer-BioNTech; coronavirus; myocarditis.